Bristol/AZ Saxagliptin Safety Review: All Signs Point to Positive Committee Outcome
This article was originally published in The Pink Sheet Daily
Executive Summary
Upcoming FDA advisory committee review of DPP4 inhibitor poses first test of new diabetes cardiovascular safety guidelines. Bristol and AstraZeneca won’t be the only companies watching carefully.
You may also be interested in...
Bristol/AZ Saxagliptin Clears Cardiovascular Safety Hurdle; Approval Timing Still Uncertain
Bristol and FDA need to agree on post-marketing cardiovascular outcomes trial for antidiabetic. Agency mum on efficacy and other safety issues.
Bristol/AZ Saxagliptin Clears Cardiovascular Safety Hurdle; Approval Timing Still Uncertain
Bristol and FDA need to agree on post-marketing cardiovascular outcomes trial for antidiabetic. Agency mum on efficacy and other safety issues.
Novo Nordisk’s Liraglutide Adds Thyroid Cancer Risk To The Diabetes Safety Gauntlet
In addition to weighing prior data against new cardiovascular outcomes standards, FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will assess April 2 whether a cancer risk in rodents translates to humans.